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Summary
Objectives—Staphylococcus aureus bacteraemia is a common, often fatal infection. Our aim
was to describe how its clinical presentation varies between populations and to identify common
determinants of outcome.
Methods—We conducted a pooled analysis on 3395 consecutive adult patients with S. aureus
bacteraemia. Patients were enrolled between 2006 and 2011 in five prospective studies in 20
tertiary care centres in Germany, Spain, United Kingdom, and United States.
Results—The median age of participants was 64 years (interquartile range 50–75 years) and
63.8% were male. 25.4% of infections were associated with diabetes mellitus, 40.7% were
nosocomial, 20.6% were caused by methicillin-resistant S. aureus (MRSA), although these
proportions varied significantly across studies. Intravenous catheters were the commonest
identified infective focus (27.7%); 8.3% had endocarditis. Crude 14 and 90-day mortality was
14.6% and 29.2%, respectively. Age, MRSA bacteraemia, nosocomial acquisition, endocarditis,
and pneumonia were independently associated with death, but a strong association was with an
unidentified infective focus (adjusted hazard ratio for 90-day mortality 2.92; 95% confidence
interval 2.33 to 3.67, p < 0.0001).
Conclusion—The baseline demographic and clinical features of S. aureus bacteraemia vary
significantly between populations. Mortality could be reduced by assiduous MRSA control and
early identification of the infective focus.
Keywords
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Introduction
Staphylococcus aureus is one of the commonest causes of nosocomial and community-
acquired bloodstream infection worldwide.1 It is a heterogenous clinical entity that is
characterized by a superficial or deep-seated focus of S. aureus infection with concomitant
bloodstream invasion causing bacteraemia. The infection is notoriously hard to treat,
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requiring prompt source control (rapid removal of colonized intravenous catheters or
drainage of pus, for example) and often prolonged antimicrobial therapy.2 Despite these
efforts, SAB is associated with a 20–30% mortality.3
The factors which determine outcome from SAB at the start of treatment have been widely
studied and include older age, comorbidities, and the nature of the infection focus.4
Subsequent clinical management may also have a major impact on outcome. For example,
timely removal of intravascular catheters, appropriate antimicrobial therapy, and
involvement of an infectious disease specialist in the management have all been reported to
improve outcome.5–7
However, there are few data describing how the clinical presentation and outcome of SAB
varies between centres and countries. In a first step, we combined data from five prospective
hospital-based cohort studies describing 3395 episodes of SAB from 20 hospitals in four
countries. Our aim was to describe the clinical presentation of SAB and to determine the
factors which mostly strongly influenced outcome.
Methods
Individual patient data from five independent, prospective cohort studies carried out in 20
study centres between 2006 and 2011 were obtained, harmonized and analysed. Data was
obtained from the Invasive Staphylococcus aureus Infection Cohort (INSTINCT) with two
sites in Germany, two studies from Spain (denoted ES1 and ES2), the United Kingdom
Infection Research Group (UKCIRG) with 15 sites in the United Kingdom, and the
Staphylococcus aureus Bacteremia Group (SABG) with one site in the United States.
Methodology and partial data of all studies have been published previously.7–11 All study
sites were tertiary referral centres of different sizes (median of 306,000 bed days per year;
range 170,000–542,000 in 2010) and operated an infectious diseases or clinical
microbiology consultation service for all patients with SAB.
Ethical considerations
The individual studies were approved by the respective institutional review boards according
to local research guidelines.7–11 Ethical standards set by the Helsinki Declaration of 1975, as
revised in 2004, were met.
Data acquisition and definitions
In all centres, clinical data from consecutive patients were collected prospectively by the
infectious diseases or clinical microbiology consultation team, according to their respective
study protocols, and either entered directly into a secure electronic database7–10 or first
documented on paper.11
In all centres, patients were eligible for the study if they were at least 18 years of age and
had at least one blood culture positive for S. aureus with accompanying clinical symptoms
and signs of infection. Patients were excluded from the analysis if an additional clinically
significant bacterial pathogen was isolated from the blood culture, if the patient was not
admitted to the hospital within three days of the first positive blood culture, or if SAB was a
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recurrence of a previously included episode. Patients with incomplete core data (missing
date of birth, gender, infective focus, methicillin susceptibility, admission date, and follow-
up information) were also excluded from analysis.
Despite similar entry and exclusion criteria, the clinical variables available for analysis
differed according to each study’s respective protocols. Before merging the datasets, a
minimum core dataset was agreed which could be reliably extracted from each study’s
dataset (Table 1). In all studies similar baseline variables were collected, with high-quality
information on the initial infective focus, but with variable data concerning subsequent
management. Data on antimicrobial treatment was not documented uniformly and was
therefore not included in the core dataset. Given the limitations imposed by the differences
between datasets, we concentrated on the core baseline variables that were likely to
influence outcome.
Clinical definitions were applied across the merged dataset. SAB was considered
nosocomial when the first positive blood culture was taken at least 48 h after hospital
admission.12 All other cases were considered “community-acquired” and treated as one
group, since health-care associated SAB could not be accurately defined retrospectively
across all centres. Injection drug use and diabetes mellitus were defined as documented
condition before the first positive blood culture.
The infective focus was defined as the site of infection considered most likely to be
responsible for seeding S. aureus into the bloodstream based on clinical signs,
microbiological findings, and imaging results. We did not use the term “portal of entry” or
“source” as the primary entry of the organism may have occurred sometime in the past and
often remains undetected. The infective focus was classified into six categories: (i) infective
endocarditis (assessed according to the modified Duke criteria13), (ii) osteoarticular
(including all bone and joint infections with or without prosthetic devices), (iii) pneumonia,
(iv) skin and soft tissue infection (SSTI), (v) central venous catheter, (vi) peripheral venous
catheter. All other foci (such as central nervous system infection, intravascular implant
infection, lung abscess, urinary tract infection) were grouped as “other focus”, because there
were less than 5% of cases for each entitity and definitions differed between studies. In
patients with multiple foci, a dominant focus was determined according to the following
ranking: endocarditis > osteoarticular > pneumonia > other focus > SSTI > central venous
catheter > peripheral venous catheter.
Patients were followed for at least three months. The primary outcome of interest was death
within three months from the first positive blood culture. Outcome was assessed either by a
telephone or written contact with the patient or next of kin, the use of hospital records, or
death register data.
Statistical analysis
Whilst a written analysis plan is lacking, the mainstay of our statistical approach was agreed
upon prior to the start of analysis. Descriptive statistics included counts and percentages for
qualitative variables and quartiles (i.e. 25th, 50th, and 75th percentiles) for quantitative data.
Chi-square and Kruskal–Wallis tests were used to compare the different studies respectively
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groups. Survival was described by Kaplan–Meier (curve) estimates, supplemented by patient
numbers at risk and the logrank test. Univariable as well as multivariable Cox regression
models stratified by study were fitted to the data to evaluate specific risk factors. Pooling of
individual patient data was done adopting both a one-stage approach (i.e. multivariable Cox
model stratified by study; regarding risk factor information) and a two-stage approach (i.e.
study-specific Kaplan–Meier (curve) estimates, random effects model for meta-analysis,
Forest plot; regarding mortality data).14 Measures of heterogeneity (I-square) and
“explained variation” (R-square) were calculated as appropriate. Due to the small number of
missing values for diabetes mellitus and injection drug use (59 values in 49 patients) we did
not impute the missing values. A p-value ≤0.05 was considered significant albeit not
corrected for multiple testing. Calculations were done in R 2.14.2 (R Foundation for
Statistical Computing, Vienna, Austria) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
A merged database was constructed with 3395 evaluable patients with SAB from 3544
eligible records (Fig. 1). Overall, 149 patients (4.2%) were excluded due to incomplete core
data. Incomplete core data were found in UKCIRG (147 cases), ES2, and SABG (1 case
each).
Baseline demographic and clinical variables
Baseline demographic and clinical variables are listed separately for each study (Table 1).
The median age of patients was 64 years (interquartile range 50–75 years) and 63.8% were
male. Overall, 698 (20.6%) cases were caused by MRSA, with the lowest percentage
reported by the German INSTINCT study (12.0%) and the highest by the SABG study from
the US (54.7%). 1383 infections (40.7%) were acquired in hospital, but this varied
significantly from 20.4% in the US study to 56.5% in one of the Spanish studies. Two of the
major risk factors for SAB – intravenous drug use and diabetes mellitus – also varied
significantly between studies, with the UK study reporting the highest proportion of
intravenous drug users (8.8%). Overall, 856 (25.4%) of patients had diabetes mellitus, with
the highest proportion (40.7%) recorded in the US study and the lowest in the UK study
(20.7%).
The infective focus at the time of the initial bacteraemia is a key determinant of treatment
strategy and prognosis. In this series, the most common dominant focus was a central or
peripheral intravenous catheter (mean 27.7% overall; study range 22.8%–39.3%) (Table 1).
The proportion of cases caused by a central venous catheter (18.8% overall), varied far less
between studies (16.1%–20.1%) than the proportion caused by peripheral venous catheters
(2.7%–23.2%). SSTI were judged the primary focus for SAB in 502 (14.8%) of cases, with
the highest proportion (19.5%) of cases reported in the UK. Endocarditis, a serious
manifestation of SAB, was diagnosed in 8.3% of all cases, ranging from 5.7% reported in
the UK to 11.6% reported in the US study. Pneumonia was present in 178 (5.2%) of patients
with the highest proportion (12.8%) reported in the US study.
In a substantial number of patients (18.9% overall) a focus of SAB was not identified, with
relatively modest inter-study variation of 15.8% (US study) to 20.1% (one of the Spanish
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studies). The identification of sometimes cryptic infective foci requires the timely
deployment of appropriate imaging techniques. One of the key investigations in these
circumstances is echocardiography and, although 56.8% of all patients in this series had an
echocardiogram, this varied significantly across the studies from 43.3% to 79.3%.
Unfortunately, data concerning other investigations (such as computed tomography and
magnetic resonance imaging) were not available across all the datasets.
Outcomes
The median duration of stay in hospital after the first positive blood culture was 16 days
(interquartile range (IQR) 8–29 days). The median duration of stay was shortest in the US
study at 10 days (IQR 6–18 days) and longest in the German (median 18 days, IQR 10–31)
and UK studies (median 17 days, IQR 9–32).
Mortality differed significantly between studies (Fig. 3) and therefore, analysis of mortality
was stratified by study. Overall, mortality increased from 9.4% by 7 days (range between
studies of 7.3%–12.5%) to 29.2% (range 22.2%–39.9%) by 90 days from the first positive
blood culture. Unadjusted analysis (Table 2) showed that age, MRSA bacteraemia,
endocarditis, pneumonia, “other” focus (other than intravenous catheter, osteoarticular
infection, SSTI, pneumonia, and endocarditis), or an unidentified focus were significantly
associated with death by each time point (days 7–90).
Mortality was dependent on infective foci with the highest mortality with pneumonia, when
an infective focus was not be identified, and with endocarditis; lower mortality was
associated with central and peripheral venous catheter-related infection, SSTI, and
osteoarticular infection (Fig. 2).
Patients with an unidentified infective focus were significantly older (median age 68 vs. 63
years, p < 0.0001), had less injection drug use (3% vs. 6.2%, p = 0.002), less diabetes
mellitus (19.9% vs. 26.7%, p = 0.0004), and a significantly poorer outcome (45.9% vs.
25.3% crude 90-day mortality, p < 0.0001) than patients where a focus was assigned.
Additionally, echocardiography was performed to a lesser extent (44.0% vs. 59.7%, p <
0.0001).
An adjusted analysis (Table 3) revealed that age, endocarditis, pneumonia, or an unidentified
focus were independently associated with death across all the time points, with pneumonia
as the strongest predictor of death at each time point (hazards ratios ranging from 5.84 by
day 14 to 4.02 by day 90). “Other” focus was significantly associated with death at 14, 30,
and 90 days; MRSA bacteraemia by day 7, 30, and 90; and intravenous drug use by day 7,
but not after this time. Conversely, nosocomial infection was only significantly associated
with death by day 30 and 90, but not at earlier time points.
Interestingly, diabetes mellitus was not associated with poorer outcome from SAB. Diabetic
patients were older (median age 67 versus 63 years, p < 0.0001), more likely to have SAB
secondary to SSTI (156 of 856, 18.2% versus 340 of 2513, 13.5%, p = 0.0008), and more
likely to suffer from MRSA infections than non-diabetic patients (29.7% vs. 17.4%, p <
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0.0001), yet, their survival was similar to non-diabetic patients (90-day mortality 30.1% vs.
28.7%, p = 0.46).
Discussion
We report the largest international patient-data based analysis of clinical characteristics and
outcome in bacteraemic S. aureus infection. Our analysis confirms several previous
observations for SAB – for example, it is an infection of older people that is more common
in men, it is most commonly caused by colonized intravenous catheters, and it is associated
with substantial mortality.15–18 However, we reveal some important differences in the
presenting clinical features of SAB in the populations studied, and highlight the critical and
potentially modifiable determinants of outcome from this serious infection.
We found some of the features of SAB were relatively consistent across the study
populations, such as the predilection for older, male patients. Other features, such as the
proportion of patients with diabetes mellitus, MRSA, or nosocomial infections, varied
substantially. Strengthened hospital infection control practices can have a major impact on
the incidence of nosocomial/MRSA infections, as evidenced by the dramatic decline in
MRSA bacteraemia in the UK over the last 5 years.19 Variation in these practices may
explain the differences in nosocomial/MRSA bacteraemia rates between the studies;
although, so too might bacterial strain variation. For example, community-acquired MRSA
infection is much more common in the US than the UK because of particular MRSA strains
(e.g. USA300) circulating in the community in the US.20 This may explain the high
percentage of MRSA infection in the US study (54.7%), and the relatively low proportion of
nosocomial infections (20.4%). Future studies aimed at understanding why the clinical
presentations of SAB vary between centres will need to take infection control practices and
bacterial strain type into account.
In accordance with previous studies,15,21,22 patients with MRSA infection had a
significantly higher mortality, even after adjustment for confounders (Table 3). Whether this
is due to the delayed receipt of appropriate antimicrobials, less effective antimicrobials,
confounding risk factors linked with the acquisition of MRSA, poorer quality of medical
care for patients in contact-isolation, or study design, has been debated extensively.16,23–25
These observations are not explained by differences in the proportions of patients with
diabetes mellitus, although diabetes mellitus was significantly more common in patients
with MRSA infection, which is in contrast to previously published findings.26
The infective focus has a well-described relationship with outcome from SAB and this is
well illustrated by comparison of the survival curves for the different foci in Fig. 2. From the
perspective of clinical practice, the most intriguing finding was the strong relationship
between death and the absence of an identified focus. Others have reported this
association,27,28 but it carries particular significance when arising from a large, multi-centre
dataset and may have a number of explanations. First, patients where an infective focus was
not identified are older than patients with an assigned focus and thus carry a higher risk of
death. In some cases, death may have intervened before the necessary investigations to
determine the site of infection could be performed, but this was unlikely to have been the
Kaasch et al. Page 7
J Infect. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
case in all patients with unknown focus as the survival curves demonstrate continued
mortality beyond 14 days from the date of the first positive blood culture (Fig. 2). In other
patients, investigations to identify an infective focus may have been insufficient and the
perceived absence of a deep-seated infective focus may have led to inadequate surgical
management or duration of antimicrobial therapy. In a recent study, 18F-FDG PET/CT scan
was used in the diagnostic pathway and significantly more metastatic foci were found and
treated, which resulted in a lower mortality and lower relapse rate compared to a historical
control.29 Our finding highlights the clinical importance of defining the infective focus early
in the course of treatment. Thus, newer imaging techniques such as PET/CT may be useful,
when conventional imaging has failed to identify the focus.
We recognize the study has some important limitations. Patients were from tertiary care
medical centres exclusively and results may only be valid for this group. The differences in
the data collected by each study restricted the extent of the shared dataset and the
conclusions drawn from the analysis. For example, we were unable to determine whether
infections were health-care associated and this group has to be merged with infections
assumed to be community-acquired. Furthermore, only limited data were available
describing disease comorbidities and disease severity at SAB onset, and data on
antimicrobial treatment and surgical management were not recorded uniformly. Therefore,
confounding from unmeasured variables may have influenced the results, and although we
observed differences in mortality between the studies (Table 1, Fig. 3) we were unable to
explain them. Another limitation is the lack of a written analysis plan. Although, the
mainstay of our analysis was pre-conceived, the lack of a written analysis plan holds the
possibility of inflating the type I error by multiple testing, especially since for the sake of
preserving power p-values were not adjusted.
In summary, this study confirms that substantial variation exists across centres with respect
to the proportion of SAB associated with diabetes mellitus, acquired in hospital and caused
by MRSA, and the infection foci responsible for the bacteraemia. It also confirms that SAB
is a common and serious infection with a high mortality, the strongest predictors of which
are pneumonia and the absence of an identified infective focus. Future investigations are
required to understand whether the variations in mortality between centres and study
populations are driven by inherent differences in baseline comorbidities and disease
severity, or are linked to modifiable factors such as adequate antimicrobial therapy and
identification and removal of the infective focus. Such studies will require prospective
standardized collection of a core clinical dataset across multiple centres in different
countries and are currently underway under the auspices of the International S. aureus
collaboration (ISAC).
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Figure 1.
Flow diagram of patients enrolled in the different studies.
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Figure 2.
Kaplan–Meier survival plot up to 90 days by dominant infective focus (p<0.0001, logrank
test). Censored cases (patients lost to follow-up) are denoted by +.
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Figure 3.
Forest plot for 30-day mortality by study.
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